ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
27.90
-0.52 (-1.83%)
At close: May 15, 2026, 4:00 PM EDT
27.87
-0.03 (-0.11%)
After-hours: May 15, 2026, 4:10 PM EDT

ArriVent BioPharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22
Selling, General & Admin
27.1924.1815.39.716.47
Research & Development
129.68153.357964.8830.43
Total Operating Expenses
156.87177.5394.3174.5936.91
Operating Income
-156.87-177.53-94.31-74.59-36.91
Interest Income
11.6311.2313.825.26-
Total Non-Operating Income (Expense)
11.6311.2313.825.26-
Pretax Income
-145.24-166.31-80.49-69.33-36.91
Net Income
-145.24-166.31-80.49-69.33-36.91
Net Income to Common
-145.24-166.31-80.49-69.33-36.91
Shares Outstanding (Basic)
41383121
Shares Outstanding (Diluted)
41383121
Shares Change (YoY)
22.44%22.22%1369.88%67.64%-
EPS (Basic)
-3.47-4.32-2.56-32.38-28.90
EPS (Diluted)
-3.47-4.32-2.56-32.38-28.90
Shares Outstanding
45.3142.4533.712.752.6
Free Cash Flow
-134.47-160.59-70.21-55.84-43.63
Free Cash Flow Per Share
-3.26-4.18-2.23-26.08-34.16
EBITDA
-156.87-177.53-94.31-74.59-36.91
EBIT
-156.87-177.53-94.31-74.59-36.91
Updated May 11, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q